Pharmafile Logo

TVF Communications

- PMLiVE

Gilead’s remdesivir not included in WHO’s COVID-19 drug scheme

Remdesivir not included as a priority drug, Reuters reports

- PMLiVE

Novartis’ canakinumab failed to improve survival in COVID-19 study

Swiss pharma company had been studying drug in hospitalised COVID-19 patients

- PMLiVE

Merck strengthens oncology pipeline with $2.75bn VelosBio deal

The deal will give Merck control of VLS-101, an antibody-drug conjugate

Commercial Execution Strategies During & After the Pandemic

Frank Armenante, Director of Commercial Execution at Novo Nordisk, discusses a range of topics, from the impact of COVID-19 on commercial operations and the digitization of Pharma to his leadership lessons...

Impetus Digital

A Lucid Group Thirsty Thursday: change management and self-efficacy

Last week, Lucid Group were lucky enough to have Richard Nugent, Founder and Managing Director of TwentyOne Leadership, present a session on change management and self-efficacy. Richard often works with...

Lucid Group Communications Limited

- PMLiVE

EMA will assess potential COVID-19 vaccine on ‘case by case’ basis

Agency will not specify a minimum level of efficacy, according to Reuters

- PMLiVE

FDA briefing documents back Biogen’s Alzheimer’s drug aducanumab

Documents show the efficacy data for the drug as being ‘exceptionally persuasive’

- PMLiVE

AZ is expecting late-stage COVID-19 vaccine data this year

Company reiterated timeline in third quarter results

- PMLiVE

The new world of association congresses

It’s time we reimagined the rules of engagement

- PMLiVE

Sanofi set to acquire Kiadis for €308m

Acquisition will see French pharma gain access to NK-cell platform

- PMLiVE

Pfizer, Mylan move ahead with generics merger and spin-out

The merger had faced a set-back as a result of COVID-19 disruption

- PMLiVE

NHS gearing up for possible pre-Christmas COVID-19 vaccinations

NHS chief exec said the NHS is getting ready to administer vaccines

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links